Press Releases

 
Press Releases
Date Title and Summary View
Sep 1, 2015 SALT LAKE CITY, Sept. 1, 2015 (GLOBE NEWSWIRE) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (Nasdaq:MYGN), announced that Elena Hitraya M.D., Ph.D., has joined the Company as the chief medical officer of Crescendo Bioscience, effective October 1, 2015. She will report to Bernie Tobin, president of Crescendo Bioscience...
Aug 13, 2015 SALT LAKE CITY, Aug. 13, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that Noridian, the Medicare Administrative Contractor (MAC) for Myriad, has issued a final local coverage determination (LCD) for Prolaris®, Myriad's pioneering prognostic test for assessing the aggressiveness of prostate cancer. This decision...
Aug 11, 2015 Total Revenues of $189.9 Million Adjusted Diluted EPS of $0.41 and Diluted EPS of $0.26 myRisk™ Hereditary Cancer Panel Ended Fourth Quarter at 72 Percent ConversionCompany Provides Fiscal Year 2016 and Fiscal First-Quarter 2016 Financial Guidance SALT LAKE CITY, Aug. 11, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today ...
Jul 29, 2015 SALT LAKE CITY, July 29, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that it will issue financial results for the fiscal fourth quarter and full year 2015 and provide a business update following the close of market on Tuesday, August 11, 2015. The Company also will host a conference call at 4:30 p.m. ET on Augus...
Jun 24, 2015 WASHINGTON and SALT LAKE CITY, June 24, 2015 (GLOBE NEWSWIRE) -- Chris4Life Colon Cancer Foundation, a Washington, D.C.-based national non-profit organization, and Myriad Genetics, a leader in personalized medicine, today announced their "What's Your History" family history week (June 24-30, 2015). "What's Your History" is an educational campaign t...
May 29, 2015 SALT LAKE CITY, May 29, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced it will highlight several new clinical studies on its myRisk Hereditary Cancer molecular diagnostic test at the 2015 American Society of Clinical Oncology annual meeting being held in Chicago, Ill. The myRisk Hereditary Cancer test assesses 25 g...
May 29, 2015 SALT LAKE CITY, May 29, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced new clinical studies on its myChoice HRD companion diagnostic test at the 2015 American Society of Clinical Oncology annual meeting being held in Chicago, Ill. Myriad's myChoice HRD test is the first and only companion diagnostic to measure thre...
May 28, 2015 SALT LAKE CITY, May 28, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Mark Capone, president of Myriad Genetics Laboratories, is scheduled to present at the Goldman Sachs Healthcare Conference at 10:40 a.m. Pacific on June 9, 2015, at the Terranea Resort in Rancho Palos Verdes, California. The presentation wi...
May 15, 2015 SALT LAKE CITY, May 15, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today presented clinical data for its Prolaris test at the 2015 American Urological Association (AUA) Annual Meeting being held May 15 to 19 in New Orleans, La. The results highlighted and underscored the significant ability of the Prolaris test to help physicians ...
May 13, 2015 SALT LAKE CITY, May 13, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced it will present data from 19 clinical studies at the 2015 American Society of Clinical Oncology annual meeting to be held May 29 to June 2, 2015 in Chicago, Ill. Key podium presentations will highlight new prospective research programs with advanced...
Page:
1
... NextLast
= add release to Briefcase